文献速递药物相互作用抗栓抗凝管理药物不良反应与药物警戒

直接口服抗凝药与氟喹诺酮类或大环内酯类抗生素联用的出血事件

Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics.
PubMed 文献 · Br J Clin Pharmacol · 2022-10-09

结果显示,氟喹诺酮类联用DOAC的出血风险即使存在也较小,大环内酯类联用未显示出血风险增加,但因大环内酯类使用者数量少,结果需谨慎解读。

要点

  • 氟喹诺酮类联用DOAC的出血风险即使存在也较小。
  • 大环内酯类联用DOAC未显示出血风险增加,但使用者数量少需谨慎。
  • 研究采用多西环素作为阴性对照,随访窗口最长150天。

核心结论

  • 氟喹诺酮类与DOAC联用时出血风险即使存在也较小。
  • 大环内酯类与DOAC联用未显示出血风险增加,但因使用者少需谨慎解读。

研究设计与样本

  • 以多西环素为阴性对照,采用Cox回归计算粗风险比和调整风险比(aHR),随访窗口为不同长度。

主要发现

  • 氟喹诺酮类和大环内酯类的出血发生率分别为每10万患者12-24例和12-53例(各随访窗口)。
  • 氟喹诺酮类联用窗口aHR为1.29(95%CI 0.69-2.44),30天为1.31(0.84-2.03),150天为1.34(0.99-1.82)。
  • 大环内酯类联用窗口aHR为2.60(95%CI 0.74-9.08),30天为1.79(0.75-4.29),150天为1.28(0.62-2.65)。

临床怎么用

  • 临床联用氟喹诺酮类与DOAC时,出血风险较小,但仍需常规监测。
  • 联用大环内酯类与DOAC时,现有证据未显示出血风险增加,但应结合患者个体情况评估。

局限性

  • 大环内酯类使用者数量少,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fluoroquinolones and macrolides may, due to a potential drug-drug interaction, increase the concentration of any concomitantly administered direct oral anticoagulant (DOAC) and thereby increase the risk of severe bleeding. However, clinical evidence for such an effect is scarce. The present study aimed to evaluate the association between the use of fluoroquinolones or macrolides and bleeding events in patients with concomitant DOAC use. This was a nationwide cohort study including 19 288 users of DOACs in 2008-2018 using information from Swedish national health registers. We compared the incidence of bleeding events associated with use of fluoroquinolones or macrolides using doxycycline as a negative control. Cox regression was used to calculate crude and adjusted hazard ratios (aHRs) in time windows of various length of follow-up after the start of antibiotic use. The incidence rates for fluoroquinolones and macrolides ranged from 12 to 24 and from 12 to 53 bleeding events per 100 000 patients in the investigated time windows. The aHRs (95% confidence interval) for use of fluoroquinolones and macrolides were 1.29 (0.69-2.44) and 2.60 (0.74-9.08) at the concomitant window, 1.31 (0.84-2.03) and 1.79 (0.75-4.29) at 30 days, and 1.34 (0.99-1.82) and 1.28 (0.62-2.65) at 150 days, respectively. With regard to fluoroquinolones, the present study suggests that the risk of bleeding when combined with DOACs, if any, is small. Codispensation of macrolides in patients on DOACs was not associated with an increased risk of bleeding. However, due to the small number of macrolide users, the results must be interpreted with caution.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yagi T, Mannheimer B, Reutfors J, et al. Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics. Br J Clin Pharmacol. 2022. PMID: 36098510. doi:10.1111/bcp.15531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。